Does sphingosine kinase 1 (SPHK1) play a role in endometriosis? Spielt sphingosinkinase 1 (SPHK1) eine potenzielle rolle bei endometriose?

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 10, 2009, Pages 935-939

  Gaetje, R ^a   Holtrich, U ^a   Engels, K ^a   Ruckhaeberle, E ^a   Rody, A ^a   Karn, T ^a   Kaufmann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Adenomyosis; Endometrium; Peritoneum; S1P; Sphingolipids

Indexed keywords

POLYCLONAL ANTIBODY; SPHINGOSINE KINASE 1;

ADENOMYOSIS; ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; ENDOMETRIOSIS; ENDOMETRIUM CELL; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PERITONEUM CELL; PROTEIN EXPRESSION;

EID: 70350444565     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1186175     Document Type: Article

References (17)

1. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604-616
2. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150
3. Alemany R, van Koppen CJ, Danneberg K et al. Regulation and functional roles of sphingosine kinases. Naunyn-Schmiedeberg's Arch Pharmacol 2007; 374: 413-428
4. Kawamori T, Kaneshiro T, Okumura M et al. Role for sphingosine kinase 1 in colon carcinomgenesis. FASEB J 2009; 23: 405-414
5. Cuvillier O. Sphingosine kinase-1 - a potential therapeutic target in cancer. Anticancer Drugs 2007; 18: 105-110
6. Smicun Y, Gil O, Devine K et al. SIP and LPA have an attachment-dependent regulatory effect on invasion of epithelial ovarian cancer cells. Gynaecol Oncol 2007; 107: 298-309
7. Ruckhäberle E, Rody A, Engels K et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112: 41-52
8. Gaetje R, Kotzian S, Herrmann G et al. Invasiveness of endometriotic cells in vitro. Lancet 1995; 346: 1463-1464
9. Gaetje R, Holtrich U, Engels K et al. Endometriosis may be generated by mimicking the ontogenetic development of the female genital tract. Fertil Steril 2007; 87: 651-656
10. Gaetje R, Holtrich U, Karn T et al. Characterization of WNT7A expression in human endometrium and endometriotic lesions. Fertil Steril 2007; 88: 1534-1540
11. Gaetje R, Holtrich U, Engels K et al. Differential expression of claudins in human endometrium and endometriosis. Gynecol Endocrinol 2008; 24: 442-449
12. Gaetje R, Holtrich U, Engels K et al. Expression ofmembrane-type 5 matrix metalloproteinase in human endometrium and endometriosis. Gynecol Endocrinol 2007; 23: 567-573
13. Burney RO, Talbi S, Hamilton AE et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 2007; 148: 3814-3826
14. Bulun SE. Endometriosis. N Engl J Med 2009; 360: 268-279
15. Olivares C, BilotasM, Buquet R et al. Effects of a selective cycloxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hm Reprod 2008; 23: 2701-2708
16. Dogan E, Saygili U, Posaci C et al. Regression of endometrial explants in rats treated with cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 2004; 82: 1115-1120
17. Ozawa Y, Murakami T, Tamura M et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 2006; 86: 1146-1151